| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20,5 k € | -50.0% | 41,0 k € | -11.1% | 46,1 k € | +19.1% | 38,7 k € | +1.3% | 38,2 k € | -44.1% | 68,3 k € | -10.7% | 76,5 k € | +1.2% | 75,6 k € | +10.7% | 68,3 k € | 0.0% | 68,3 k € | 0.0% | 68,3 k € | |
| Gross margin | 12,8 k € | -59.2% | 31,3 k € | -4.0% | 32,7 k € | +4.3% | 31,3 k € | -0.3% | 31,4 k € | -46.2% | 58,3 k € | -13.8% | 67,7 k € | +8.7% | 62,2 k € | +0.5% | 61,9 k € | -4.4% | 64,7 k € | -2.7% | 66,5 k € | |
| EBITDA | 12,4 k € | -59.9% | 31,0 k € | -4.2% | 32,3 k € | +4.4% | 31,0 k € | +4.2% | 29,7 k € | -48.8% | 58,0 k € | -13.4% | 67,0 k € | +8.7% | 61,6 k € | +0.2% | 61,5 k € | -4.4% | 64,3 k € | -2.7% | 66,1 k € | |
| Operating profit | 12,4 k € | +154.6% | -22,7 k € | -6.3% | -21,4 k € | +6.0% | -22,7 k € | +9.4% | -25,1 k € | -684.2% | 4,3 k € | -66.9% | 13,0 k € | +70.1% | 7,6 k € | +1.5% | 7,5 k € | -27.3% | 10,3 k € | -14.6% | 12,1 k € | |
| Profit/loss | 12,4 k € | +154.1% | -22,9 k € | +6.9% | -24,6 k € | -3.8% | -23,7 k € | +18.7% | -29,1 k € | -1675.3% | -1,6 k € | -122.2% | 7,4 k € | +375.0% | 1,6 k € | +309.2% | 380,0 € | -75.7% | 1,6 k € | +608.6% | 221,0 € | |
| Equity | -72,2 k € | +14.6% | -84,6 k € | -37.1% | -61,7 k € | -66.2% | -37,1 k € | -175.9% | -13,5 k € | -186.0% | 15,7 k € | -9.5% | 17,3 k € | +74.4% | 9,9 k € | +18.6% | 8,4 k € | +4.8% | 8,0 k € | +24.4% | 6,4 k € | |
| Total assets | 137,5 k € | -6.8% | 147,5 k € | -23.2% | 192,2 k € | -14.4% | 224,5 k € | -16.8% | 269,9 k € | -19.6% | 335,6 k € | +19.2% | 281,4 k € | -15.3% | 332,2 k € | -15.8% | 394,4 k € | -28.2% | 549,6 k € | -7.9% | 596,5 k € | |
| Cash | 180,0 € | +2150.0% | 8,0 € | -80.0% | 40,0 € | — | 0,0 € | -100.0% | 98,0 € | -12.5% | 112,0 € | -91.2% | 1,3 k € | +221.7% | 397,0 € | -70.1% | 1,3 k € | +1035.9% | 117,0 € | |||
| Debts | 209,7 k € | -9.7% | 232,2 k € | -8.6% | 253,9 k € | -3.0% | 261,7 k € | -7.7% | 283,3 k € | -11.4% | 319,9 k € | +21.1% | 264,1 k € | -18.0% | 322,3 k € | -16.5% | 386,0 k € | -28.7% | 541,6 k € | -8.2% | 590,1 k € | |
Source: Belgian Official Gazette
Private company with limited liability · Lubbeek · incorporated on 22/01/2014
Private company with limited liability with a balanced profile. Cash position rising (+2150.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Beisol Pharma Meerle is a Private company with limited liability incorporated in 2014. Its main activity is: Leasing of intellectual property and similar products, except copyrighted works. Its registered office is in Lubbeek.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.